Jun 22, 2017 4:05pm EDT Rigel Announces Oral Presentation of TAVALISSE™ (fostamatinib disodium) Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress
Jun 19, 2017 7:30am EDT FDA Accepts Rigel's New Drug Application for TAVALISSE™ (fostamatinib disodium) for the Treatment of Chronic ITP
May 02, 2017 4:01pm EDT Rigel Announces First Quarter 2017 Financial Results and Provides Company Update
Apr 27, 2017 7:30am EDT Rigel Announces Tavalisse™ as Proprietary Name for Fostamatinib in the United States
Apr 25, 2017 7:30am EDT Rigel Announces Conference Call and Webcast to Report First Quarter 2017 Financial Results
Mar 07, 2017 4:01pm EST Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and Provides Company Update
Feb 28, 2017 7:30am EST Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2016 Financial Results
Feb 03, 2017 4:01pm EST Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
